PharmaCyte Biotech, Inc. (PMCB): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:28 ET
- Event date
- 2026-11-10
- Accession no.
- 0001683168-26-008705
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
PharmaCyte Biotech effects 1-for-19 reverse stock split
PharmaCyte Biotech disclosed a 1-for-19 reverse stock split effective November 12, 2026, with split-adjusted trading beginning November 13, 2026. Authorized shares were unchanged, and stockholders entitled to fractional shares will receive cash instead. The company said the split is intended to regain compliance with Nasdaq’s minimum bid price requirement.
- The 1-for-19 reverse stock split became effective at 4:01 p.m. Eastern Time on November 12, 2026.
- Common stock began trading on a split-adjusted basis on November 13, 2026, under the symbol PMCB.
- Authorized shares and par value per share were unchanged; fractional shares are payable in cash.
- Proportionate adjustments were made to outstanding options, warrants, convertible securities and equity incentive plans.
governanceother
Items reported
- Item 3.03: Material Modifications to Rights of Security Holders
The rights of holders of a class of the company's securities were materially modified, for example by a charter amendment, a rights plan or a reverse stock split. - Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
The company amended its articles of incorporation or bylaws without a shareholder vote that was previously disclosed, or changed its fiscal year. - Item 8.01: Other Events
A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news. - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | pharmacyte_8k.htm |
| EX-3.1 | CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION | pharmacyte_ex0301.htm |
| EX-99.1 | PRESS RELEASE | pharmacyte_ex9901.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.